Key Points Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The ...

The stock of Eli Lilly has a consensus Strong Buy rating among 19 Wall Street analysts. That rating is based on 16 Buy, two ...

President Trump has threatened to levy tariffs of up to 200% on pharmaceutical imports. Lilly's margins could be negatively ...

Eli Lilly & Co. closed 20.16% below its 52-week high of $972.53, which the company achieved on August 22nd.

Eli Lilly (NYSE: LLY) is gaining market share in a lucrative market that could be a catalyst for a stock price increase. *Stock prices used were the afternoon prices of May 14, 2025. The video was ...

Eli Lilly's stock isn't cheap. The company's stock trades at a hefty 39 times forward earnings. That's very high for a pharma company and more than twice its main GLP-1 competitor, Novo Nordisk.

Eli Lilly (LLY 1.34%) ... Plenty of reasons to buy the stock. If Eli Lilly can incorporate Camurus' FluidCrystal technology, its GLP-1 medicines might no longer need once-weekly dosing.

Eli Lilly's position in the weight management market makes its stock attractive, considering how fast this area is projected to grow in the coming years. 2. Diversifying its lineup and pipeline ...

It has a market cap of $523 billion, significantly lower than Visa and Eli Lilly. However, the stock is exchanging hands for $1,228 and is up 90% in 12 months.

Eli Lilly (NYSE: LLY) is gaining market share in a lucrative market that could be a catalyst for a stock price increase. Should you invest $1,000 in Eli Lilly right now? The Motley Fool Stock ...